Overview
Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH) is bringing together a coalition of partners to accelerate the development and manufacturing of lifesaving medicines for BC and Canada. Led by the University of British Columbia (UBC), CIEBH is one of five national research hubs established through the integrated Canada Biomedical Research Fund (CBRF) and Biosciences Research Infrastructure Fund (BRIF) competition.
CIEBH is pursuing an integrated program of biomedical research and talent development, along with building associated infrastructure to support the development and manufacturing of medical treatments in BC and Canada. The Hub will be a strategic partner that facilitates connections between industry, academia, governments and healthcare institutions.
Vision & Mission
CIEBH’s vision is to make Canada a global epicentre for developing next-generation immune-based therapeutics that can be rapidly produced domestically, using the latest innovations in biomanufacturing, in response to future pandemics and other health threats.
Our mission is to harness the collective research and training excellence of our multidisciplinary, multisectoral partners to greatly increase Canadian capacity to translate scientific discoveries into patient-ready treatments at rapid speed — saving more lives, sooner.
The Hub’s activities are focused on three key areas:
- Increasing specialized infrastructure for applied biomedical research, including wet lab space, core technology platforms, early-stage biomanufacturing infrastructure, and clinical trials infrastructure;
- Supporting training and development of skilled talent for the biomanufacturing and life sciences ecosystem; and
- Accelerating translation of promising research into commercially viable products and processes.
For more information, please visit immunoengineeringhub.ca or contact CIEBH’s Executive Director, Dr. Michelle Wong at immunoengineering.hub@ubc.ca.